Increasingly, in vivo imaging of small laboratory animals has become critical for preclinical biomedical research allowing the non-invasive assessment of biological and biochemical processes in living subjects. Many dierent positron labeled compounds have been synthesized as tracer that target a range of specic markers or pathways yielding quantitative, spatially and temporally indexed information on normal and diseased tissues such as tumors. Because of its non-invasive nature, nuclear techniques also enable to repeat studies in a single subject, facilitating longitudinal assay designs of rodent models of human cancer, cardiovascular, neurological and other diseases over the entire process, from the inception to progression of the disease, and monitoring the eectiveness of treatment or other interventions (with each animal serving as its own control and thereby reducing biological variability). This also serves to reduce the number of experimental animals required for a particular study. In contrast to cell or tissue culture-based experiments, studies in intact animals incorporate all the interacting physiological factors present in vivo.
Introduction
Imaging has long been indispensable in clinical prac- Non-invasive in vivo validation of the candidate drugs and probes is critical prior to perform human trials.
The non-invasive nature enables one to repeat studies in a single subject, facilitating longitudinal assay designs of animal models of human diseases over the entire process, from the inception to progression, and monitoring the eectiveness of treatment or other interventions (with each animal serving as its own control and thereby reducing biological variability). This also serves to reduce the number of experimental animals required for a particular study. In contrast to in vitro and ex vivo, studies in intact animals incorporate all the interacting physiological factors present in vivo [1, 2] .
The mouse is the most used, followed by rat.
The mouse makes an excellent model for human disease * corresponding author; e-mail: marta.oteo@ciemat.es 
Challenges for small animal imaging
The most obvious challenge for small animal imaging is to visualize anatomical structures and monitor physiological activities on such small scale, so high resolution imaging modalities are required [36] . Resolution, which is dened as the distance where two innitely small point sources can still be distinguished from each other, aects not only the level of detail that can be seen in an image, but also can strongly aect quantication of radionuclide concentrations. But usually improved resolution is achieved at the expense of sensitivity which is translated in poorer signal-to-noise ratios. That's why reverse translation of clinical imaging modalities to small animal research requires substantial improvements in the dierent imaging modalities which involve re-engineering of many aspects of their hardware, rmware and software. Each modality has particular characteristics, advantages and limitations and they are generally considered complementary rather than competitive performance parameters and logistical features of small-animal imaging modalities and a comparative spatial resolution between clinical and preclinical imaging modalities and associated design renements can be found in [2] . The choice of a certain imaging modality depends primarily on the specic question to be addressed. There is a consensus among experts in the eld that the most sensitive techniques are the nuclear ones (PET and SPECT).
PET scanners for animal research
The goal in the designing of small animal PET scanners is to improve resolution while maintaining high sensitivity. This can be achieved by improvements in the detector instrumentation and overall system design by reducing the detector size and ring diameter, new scintillators and the use of iterative reconstruction methods.
Resolution and sensitivity are also aected by radiotracer characteristics as positron range and radiotracer specic activity. Positron range in tissue (being a function of the kinetic energy with which it is emitted from the nucleus) limits the spatial resolution and signicant increase in radiotracer specic activity would allow more activity to be injected into an animal, and therefore improve count- Preclinical imaging studies using PET oer the opportunity for direct translational research in molecular imaging and drug discovery from bench-to-bedside. PET can be used to characterize the pharmacodynamics and pharmacokinetics of the new molecular imaging probes and Our group has been working for several years with 68 Ga radiolabeled compounds.
Thus, in collaboration with the Melanoma Group of the National Cancer Research Center in Spain, we labeled with 68 Ga a DOTA-α-melanocyte-stimulating hormone analog (DOTA-Napamide) which has been shown to specifically bind to melanocortin receptors that are overexpressed on human and mouse melanoma cells and assayed melanocortin receptor-binding potency of the radiopeptide in a mouse model implanted subcutaneously with a melanoma cell line (Fig. 2) .
Fig. 2.
18 F-FDG uptake (A) compared to 68 Ga-DOTA-napamide uptake (B) in subcutaneously implanted melanoma. Detection of melanoma lung metastasis is shown in (C).
As it is shown in Fig. 2B , 68 Ga-DOTA-napamide image, there is almost no signal in other organs than the tumor; when the melanoma cell line was intravenously injected, lung metastasis could be detected (Fig. 2C) . Fig. 3 , where an excellent tumor tracer uptake was observed.
Conclusion
PET molecular imaging allows the non-invasive assessment of biological and biochemical processes in living subjects using dierent imaging probes to measure the expression of indicative markers at dierent stages of diseases, contributing to improve our understanding of disease and drug activity during preclinical and clinical drug development.
